Selected Start-Ups (9/01)
In Vivo summarizes the technologies of these recently founded companies:Egea Biosciences Inc. will provide gene synthesis and protein design and production for its corporate partners. ImpactRx Inc. is building networks of high-prescribing physicians that will provide real-time diagnosis, drug, and promotion information to Pharma clients. MetriGenix Inc. claims that its flow-through platform has higher hybridization rates and larger active surface areas than typical microarrays, allowing for faster analysis using smaller amounts of samples and reagents. Neuronetics Inc. will use pulsed magnetic fields to treat severe depression, marketing its technology as a noninvasive alternative to electroconvulsive therapy. TolerRx Inc. aims to combat chronic inflammatory and immune diseases by harnessing the T-cell mediated tolerance mechanisms by which the body recognizes self-antigens. Starting off with three drugs acquired from Immunex Corp., Xanodyne Pharmacal Inc. will develop and market therapeutics for cancer, bleeding disorders, pain management and other indications.
You may also be interested in...
Thermo Fisher Scientific has agreed to buy Mesa Biotech for $450m in cash and Hillrom will acquire Bardy Diagnostics for $375m in cash. Both deals will add complementary digital health solutions, which may be a continued trend in 2021.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Medicare now covers transcatheter edge-to-edge repair for both functional and degenerative mitral regurgitation under specific conditions.